Is There an Independent Role of TERT and NF1 in High Grade Gliomas?

Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta neuropathol, 131, 803, 10.1007/s00401-016-1545-1 Wesseling, 2018, WHO 2016 Classification of gliomas, Neuropathol Appl Neurobiol, 44, 139, 10.1111/nan.12432 Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710 van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229 Burris, 2015, Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas, Mol Cancer Ther, 14 Yang, 2016, Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas, Neuro Oncol, 18, 1099, 10.1093/neuonc/now021 Scheffzek, 2012, Neurofibromin: Protein domains and functional characteristics, 305 Philpott, 2017, The NF1 somatic mutational landscape in sporadic human cancers, Human Genom, 11, 13, 10.1186/s40246-017-0109-3 Zhu, 2005, Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma, Cancer cell, 8, 119, 10.1016/j.ccr.2005.07.004 Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer cell, 17, 98, 10.1016/j.ccr.2009.12.020 Eckel-Passow, 2015, Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 Wiestler, 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis, Acta Neuropathol, 126, 443, 10.1007/s00401-013-1156-z Zacher, 2017, Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel, Brain Pathol (Zurich, Switzerland), 27, 146, 10.1111/bpa.12367 Kim, 2018, Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas, Pathol Res Pract, 214, 881, 10.1016/j.prp.2018.04.002 Binabaj, 2018, The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials, J Cell Physiol, 233, 378, 10.1002/jcp.25896 Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell, 155, 462, 10.1016/j.cell.2013.09.034 Frattini, 2013, The integrated landscape of driver genomic alterations in glioblastoma, Nature Genet, 45, 1141, 10.1038/ng.2734 Killela, 2013, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal, Proc Natl Acad Sci U S A, 110, 6021, 10.1073/pnas.1303607110 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901 McGranahan, 2015, Clonal status of actionable driver events and the timing of mutational processes in cancer evolution, Sci Transl Med, 7, 283ra54, 10.1126/scitranslmed.aaa1408 Vizcaíno, 2015, Clinicopathologic implications of NF1 gene alterations in diffuse gliomas, Human Pathol, 46, 1323, 10.1016/j.humpath.2015.05.014 Cawthon, 1990, A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations, Cell, 62, 193, 10.1016/0092-8674(90)90253-B Shibahara, 2018, Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations, Brain Tumor Pathol, 35, 10, 10.1007/s10014-017-0302-z McGillicuddy, 2009, Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis, Cancer Cell, 16, 44, 10.1016/j.ccr.2009.05.009 Ceccarelli, 2016, Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma, Cell, 164, 550, 10.1016/j.cell.2015.12.028 Lee, 2017, The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas, Acta Neuropathol Commun, 5, 62, 10.1186/s40478-017-0465-1 Jeong, 2017, Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme, Oncol Lett, 14, 8213 Vuong, 2017, TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data, Crit Rev Oncol Hematol, 120, 1, 10.1016/j.critrevonc.2017.09.013 Chandler, 2013, Does your gene need a background check? How genetic background impacts the analysis of mutations, genes, and evolution, Trends Genet, 29, 358, 10.1016/j.tig.2013.01.009 Hiyama, 2009 Arita, 2016, A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas, Acta Neuropathol Commun, 4, 79, 10.1186/s40478-016-0351-2 Nguyen, 2017, Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy, Neuro Oncol, 19, 394 Park, 2012, The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas, Transl Oncol, 5, 393, 10.1593/tlo.12253